Paper41593124
Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer.
Sadetsky N and 9 others. Sci Rep, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer. Papers, record 41593124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41593124
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Triple Negative Breast Neoplasms | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Female | |
| Treatment Outcome | |
| Middle Aged | |
| Fulvestrant | |
| Paclitaxel | |
| Receptors, Progesterone | |
| Receptors, Estrogen | |
| Pyridines | |
| Aged | |
| Neoplasm Metastasis | |
| Progression-Free Survival | |
| Adult | |
| Piperazines |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31335166 | An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. | JCO Clin Cancer Inform | 2019 | https://conductscience.org/library/papers/31335166 | PubMed |
| 2 | 30959874 | Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. | Cells | 2019 | https://conductscience.org/library/papers/30959874 | PubMed |
| 3 | 30345905 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30345905 | PubMed |
| 4 | 36408668 | The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology. | Clin Pharmacol Ther | 2023 | https://conductscience.org/library/papers/36408668 | PubMed |
| 5 | 17947786 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. | BMJ | 2007 | https://conductscience.org/library/papers/17947786 | PubMed |
| 6 | 39966355 | Breast cancer: pathogenesis and treatments. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/39966355 | PubMed |
| 7 | 39146509 | Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy. | JCO Clin Cancer Inform | 2024 | https://conductscience.org/library/papers/39146509 | PubMed |
| 8 | 32546660 | Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows. | Mol Cancer Ther | 2020 | https://conductscience.org/library/papers/32546660 | PubMed |
| 9 | 37633306 | Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37633306 | PubMed |
| 10 | 28743247 | A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). | BMC Cancer | 2017 | https://conductscience.org/library/papers/28743247 | PubMed |
| 11 | 31394922 | Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. | J Comp Eff Res | 2019 | https://conductscience.org/library/papers/31394922 | PubMed |
| 12 | 35665782 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35665782 | PubMed |
| 13 | 35643624 | Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. | Clin Breast Cancer | 2022 | https://conductscience.org/library/papers/35643624 | PubMed |
| 14 | 23915742 | The management of early-stage and metastatic triple-negative breast cancer: a review. | Hematol Oncol Clin North Am | 2013 | https://conductscience.org/library/papers/23915742 | PubMed |
| 15 | 27583878 | Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. | Medicine (Baltimore) | 2016 | https://conductscience.org/library/papers/27583878 | PubMed |
| 16 | 32315295 | Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. | PLoS One | 2020 | https://conductscience.org/library/papers/32315295 | PubMed |
| 17 | 26690726 | Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases. | Clin Pharmacol Ther | 2016 | https://conductscience.org/library/papers/26690726 | PubMed |
| 18 | 34664259 | The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. | Clin Pharmacol Ther | 2022 | https://conductscience.org/library/papers/34664259 | PubMed |
| 19 | 40669020 | Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. | JCO Precis Oncol | 2025 | https://conductscience.org/library/papers/40669020 | PubMed |
| 20 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41593124
GET https://conductscience.org/api/papers/v1/41593124/references?page=2